IFG Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

IFG Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,394	Closed	-$213K	–	335
2017 Q4	$213K	Buy	+2,394	New	+$208K	0.05%	306

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IFG Advisory's BMRN Position: Q1 2018 in Review

IFG Advisory sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 2,394 shares — an estimated $213K sold.

IFG Advisory first reported a position in BMRN in Q4 2017 and held it in 1 quarter. The position peaked at $213K in Q4 2017. 429 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

IFG Advisory reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
IFG Advisory sold 2,394 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $213K.
IFG Advisory first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 1 quarter.
IFG Advisory's BioMarin Pharmaceuticals position peaked at $213K in Q4 2017.
429 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on IFG Advisory's 13F filing for Q1 2018, filed 26 Apr 2018.